Faculty profile

Terry Hawrysh

ResearcherUniversity of Ottawa

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Ottawa directory, so their courses and email address may be missing. Find their university profile.

Terry Hawrysh

Researcher

Health Sciences

University of Ottawa

Ottawa, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
3 publications in the last five years, latest in 2026.
Principal investigator on 2 research grants (2 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Access To Care Car-T Leukemia Point-Of-Care Biomanufacturing

Latest papers

Making room for patients in economic evaluation: a commentary on current capacity and future directions.
Research involvement and engagement · 2026
Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2024
CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.
Frontiers in immunology · 2022

All 7 publications

Latest funding

Developing evidence-informed patient engagement guidance for economic evaluations (DEEP-ENGAGE)
CIHR · 2024 · Co-investigator
$504,925
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
CIHR · 2022 · Principal investigator
$3,216,843
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
CIHR · 2022 · Principal investigator
$804,211

All 3 grants and awards

7 publications.

Making room for patients in economic evaluation: a commentary on current capacity and future directions.

Thompson ER, Wilson M, Nicholls SG, Fergusson DA, Lalu M, Smith M, Hawrysh T, Bede S, Halas M, Riches L, Walsh D, Presseau J, Thavorn K

Research involvement and engagement2026

DOI: 10.1186/s40900-026-00880-x PMID: 41975509

Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.

Thavorn K, Thompson ER, Kumar S, Heiskanen A, Agarwal A, Atkins H, Shorr R, Hawrysh T, Chan KK, Presseau J, Ollendorf DA, Graham ID, Grimshaw JM, Lalu MM, Nochaiwong S, Fergusson DA, Hutton B, Coyle D, Kekre N

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research2024

DOI: 10.1016/j.jval.2024.04.004 PMID: 38641057

CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.

Kekre N, Hay KA, Webb JR, Mallick R, Balasundaram M, Sigrist MK, Clement AM, Nielsen JS, Quizi J, Yung E, Brown SD, Dreolini L, Waller DD, Smazynski J, Gierc NS, Loveless BC, Clark K, Dyer T, Hogg R, McCormick L, Gignac M, Bell S, Chapman DM, Bond D, Yong S, Fung R, Lockyer HM, Hodgson V, Murphy C, Subramanian A, Wiebe E, Yoganathan P, Medynski L, Vaillan DC, Black A, McDiarmid S, Kennah M, Hamelin L, Song K, Narayanan S, Rodrigo JA, Dupont S, Hawrysh T, Presseau J, Thavorn K, Lalu MM, Fergusson DA, Bell JC, Atkins H, Nelson BH, Holt RA

Frontiers in immunology2022

DOI: 10.3389/fimmu.2022.1074740 PMID: 36601119

Hematologists' barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study.

Castillo G, Lalu M, Asad S, Foster M, Kekre N, Fergusson D, Hawrysh T, Atkins H, Thavorn K, Montroy J, Schwartz S, Holt R, Broady R, Presseau J, GO CART team

Trials2021

DOI: 10.1186/s13063-021-05121-y PMID: 33766105

Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial.

Castillo G, Lalu MM, Asad S, Foster M, Kekre N, Fergusson DA, Hawrysh T, Atkins H, Thavorn K, Montroy J, Schwartz S, Holt RA, Broady R, Presseau J

BMJ open2021

DOI: 10.1136/bmjopen-2020-043929 PMID: 33741670

Evaluation of a preoperative personalized risk communication tool: a prospective before-and-after study.

Hladkowicz E, Yachnin D, Boland L, Wilson K, McKinnon A, Hawrysh K, Hawrysh T, Bell C, Atkinson K, van Walraven C, Taljaard M, Thavorn K, Stacey D, Yang H, Pysyk C, Moloo H, Manuel D, MacDonald D, Lavallée LT, Gagne S, Forster AJ, Bryson GL, McIsaac DI

Canadian journal of anaesthesia = Journal canadien d'anesthesie2020

DOI: 10.1007/s12630-020-01809-y PMID: 32929659

Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials.

Foster M, Fergusson DA, Hawrysh T, Presseau J, Kekre N, Schwartz S, Castillo G, Asad S, Fox G, Atkins H, Thavorn K, Montroy J, Holt RA, Monfaredi Z, Lalu MM

Research involvement and engagement2020

DOI: 10.1186/s40900-020-00230-5 PMID: 33072399

Something wrong or missing on this profile? Suggest a correction

Terry Hawrysh

Research

Latest papers

Latest funding

Making room for patients in economic evaluation: a commentary on current capacity and future directions.

Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review.

CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies.

Hematologists' barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study.

Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial.

Evaluation of a preoperative personalized risk communication tool: a prospective before-and-after study.

Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials.

Developing evidence-informed patient engagement guidance for economic evaluations (DEEP-ENGAGE)

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Frequent collaborators

Kednapa Thavorn

Kednapa Thavorn

Justin Presseau

Harold Atkins

Natasha Kekre

Manoj Lalu

Jennifer Quizi

Husein Moloo

Michael Kennah

Doug Coyle

Homer Yang

Maureen Smith

Carl van Walraven

Laura Boland

Kumanan Wilson

Monica Taljaard

Brian Hutton

Dawn Stacey

Dean Fergusson